Give specialists a clearer view of the organisational question.

NICE's stewardship guidance and the UKHSA Start smart then focus toolkit provide the national context (NICE, n.d.; UKHSA, n.d.). A local evaluation should state what the team wants to improve and why the selected information is relevant. The scope might concern whether an agreed review is documented and how outstanding work is escalated. It should not assume that fewer prescriptions or a lower purchasing cost is always better care. The organisational question needs clinical ownership so a convenient measure cannot quietly become the purpose of the programme.

A recorded process measure, a specialist interpretation and a proposed improvement should be presented separately. This lets the reviewer see which statements follow directly from the information and which require professional judgement. A preparation tool should not turn incomplete organisational data into patient-specific treatment advice. The proposed brief would also identify where a source or local policy has changed. Maintaining that distinction is central to commercial usefulness: a faster draft is valuable only if specialists can understand and challenge its reasoning.

A first PHARMORIS evaluation could use public guidance, approved local process documents and synthetic or appropriately aggregated examples. Compare preparation of a stewardship review brief with the existing audit or meeting pack. Specialists would define critical facts, missing information and unacceptable inferences before assessing the outputs. The initial scope would exclude live clinical recommendations and changes to prescribing systems. It would test preparation quality and effort, while preserving the team's established audit, clinical governance and escalation responsibilities.

Stop if the draft suggests that an individual treatment should change, omits relevant context or treats a crude reduction in use as a clinical benefit. Agree tolerances for correction burden and incomplete source coverage in advance. If the evaluation shows that the team already prepares the material efficiently, a new tool may add little value. A credible commercial proposition must accept that possibility. The result should guide investment towards an actual preparation problem rather than create demand by criticising work that already functions well.

An antimicrobial pharmacist, clinical lead and audit representative can define a recurring review task and the standards its output must meet. We can discuss whether a focused comparison is feasible with permitted material. PHARMORIS remains in development; this page describes a proposed organisational application, not a clinical prescribing product or a demonstrated stewardship outcome. The potential value is time and attention directed towards a more inspectable review, with a clear decision about whether further evidence and development are justified.